» Articles » PMID: 12200065

NK Cells: a Lesson from Mismatched Hematopoietic Transplantation

Overview
Journal Trends Immunol
Date 2002 Aug 30
PMID 12200065
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

The past ten years have witnessed dramatic progress in our understanding of how natural killer (NK) cells function, their role in innate defenses and their possible exploitation in therapy. This article traces the major advances in these formerly mysterious cells, from the 'missing self' hypothesis and the first discovery of HLA-class I-specific inhibitory receptors to a recent major breakthrough that highlighted important perspectives and major expectations regarding the cure of life-threatening leukemias. The key role of 'alloreactive' NK cells in eradicating acute myeloid leukemias and in preventing both graft rejection and graft-versus-host disease, might lead to a true revolution in bone marrow transplantation. Thus, it might now be possible to search for appropriate HLA class I mismatches to set NK cells in action.

Citing Articles

AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK-cell cytotoxicity through activating receptors modulation.

Caforio M, Tumino N, Sorino C, Manni I, Di Giovenale S, Piaggio G Front Immunol. 2023; 14:1191908.

PMID: 37435061 PMC: 10332273. DOI: 10.3389/fimmu.2023.1191908.


DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.

Cifaldi L, Melaiu O, Giovannoni R, Benvenuto M, Focaccetti C, Nardozi D Front Immunol. 2023; 14:1197053.

PMID: 37359555 PMC: 10285446. DOI: 10.3389/fimmu.2023.1197053.


NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia.

Valenzuela-Vazquez L, Nunez-Enriquez J, Sanchez-Herrera J, Medina-Sanson A, Perez-Saldivar M, Jimenez-Hernandez E Front Oncol. 2022; 12:1023510.

PMID: 36419901 PMC: 9677112. DOI: 10.3389/fonc.2022.1023510.


Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?.

Damele L, Spaggiari G, Parodi M, Mingari M, Vitale M, Vitale C Cancers (Basel). 2022; 14(18).

PMID: 36139598 PMC: 9496735. DOI: 10.3390/cancers14184439.


Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells.

Maddineni S, Silberstein J, Sunwoo J J Immunother Cancer. 2022; 10(5).

PMID: 35580928 PMC: 9115029. DOI: 10.1136/jitc-2022-004693.